Eli Lilly (LLY)

The pharmaceutical and biotechnology industries are undergoing a profound transformation, driven by an urgent need for more efficient drug discovery and development processes and the paradigm shift towards personalized medicine. Artificial intelligence (AI) stands at the forefront of this revolution, offering unprecedented capabilities to overcome long-standing challenges and accelerate the delivery of tailored, effective treatments. [...]

San Francisco, CA – October 22, 2025 – Nurix Therapeutics (NASDAQ: NRIX) has captured significant market attention, with its stock experiencing a notable surge following the announcement of the initiation of its pivotal Phase 2 DAYBreak clinical study. This critical advancement focuses on bexobrutideg (NX-5948), an investigational Bruton's tyrosine kinase (BTK) degrader,

Copenhagen, Denmark – October 22, 2025 – Novo Nordisk (NYSE: NVO) shares experienced a notable decline this week following the announcement of a comprehensive board overhaul, a decisive move orchestrated by its top investor, the non-profit Novo Nordisk Foundation. The shake-up, which will see seven independent board members, including the chairman, step

Big Money Exits: Iconic Pharma Stock Sold by High-Profile Asset Manager

The rapid growth rates of recent years aren't guaranteed to continue.

Looking for high-upside stocks in 2025? AMD, UBER, and LLY each offer over 30% EPS growth potential and analyst-backed price targets with double-digit gains.

Don't try to catch a falling surgical knife.

The tides continue to change in Eli Lilly's favor in the GLP-1 space.

The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, positive market sentiment, or significant industry tailwinds.

As the financial markets gear up for the week commencing Monday, October 20, 2025, investors are keenly attuned to the insights of CNBC's Jim Cramer, a vocal and influential voice in the stock market. While a precise, real-time "Top 10" list from Cramer for this specific Monday is not publicly

The company said its breast cancer treatment delayed progression for a median of 19.7 months in some patients.

These companies are jockeying for position in a potential $150 billion market opportunity.

The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, positive market sentiment, or significant industry tailwinds.

These two high-quality stocks can deliver impressive returns in the long run.

Polio cases drop 99.9%, but funding shortfall could undo progress. Last mile hardest as virus exploits immunity gaps.

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.

The Vanguard S&P 500 Growth ETF typically outperforms the S&P 500 over the long term.

Trump's vow to slash weight-loss drug prices sent Hims & Hers tumbling. These ETFs are facing new pressure.

Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Friday.

Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 3.5% in the afternoon session after political comments introduced significant uncertainty regarding the future pricing of the company’s weight-loss and diabetes drugs, Zepbound and Mounjaro. 

Novo Nordisk offers cheap stock with strong moat and long-term growth tailwinds. Trump's drug price cut suggestion caused short-term volatility but...